Compare JFR & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JFR | NNNN |
|---|---|---|
| Founded | 2004 | 2021 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.5B |
| IPO Year | N/A | 2025 |
| Metric | JFR | NNNN |
|---|---|---|
| Price | $7.93 | $32.70 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 621.7K | 35.5K |
| Earning Date | 01-01-0001 | 04-28-2026 |
| Dividend Yield | ★ 11.31% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.06 |
| Revenue | N/A | ★ $6,920,153.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $525.34 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.61 | $5.18 |
| 52 Week High | $8.82 | $55.65 |
| Indicator | JFR | NNNN |
|---|---|---|
| Relative Strength Index (RSI) | 56.73 | 49.35 |
| Support Level | $7.79 | $30.08 |
| Resistance Level | $8.00 | $43.00 |
| Average True Range (ATR) | 0.06 | 4.23 |
| MACD | 0.00 | -0.44 |
| Stochastic Oscillator | 71.74 | 32.68 |
Nuveen Floating Rate Income Fund is a diversified closed-end management investment company. Its investment objective is to achieve a high level of current income. The fund invests a majority of its managed assets in secured Senior Loans and unsecured Senior Loans, with an average duration of one year or less, in which unsecured Senior Loans will be, at the time of investment, investment grade quality.
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions.